CAR-T

Woman reading on a laptop
#CAR-T #Cell and gene therapy #Flow Cytometry #Oncology #Quantum computing

Your top reads of 2025

With topics as diverse as quantum computing, ion channel drug discovery and antisense oligonucleotides, these were DDW readers’ most-read articles of 2025.  10. We need international partnerships to get new cancer drugs into the clinic On International Clinical Trials Day, Lars Erwig, Director of the Centre for Drug Development at… Read More

#Exclusive Content

Blood cells
#ASH 2025 #CAR-T #Events #Haematology #Oncology

ASH 2025: New clinical findings in haematology

The 67th American Society of Hematology (ASH) Annual Meeting and Exposition took place 6-9 December 2025, in Orlando, Florida. Diana Turner rounds up the latest clinical trial data shared at the meeting.  Early-stage trials KLN-1010 for multiple myeloma Kelonia Therapeutics announced the first results from the ongoing inMMyCAR study, a… Read More

#Exclusive Content

Diffuse large B-cell lymphoma
#Acute Myeloid Leukaemia #Biotech #CAR-T #Lymphoma

Imviva to present data on CAR-T pipeline 

Biotechnology company Imviva Biotech is set to present data on its CAR-T pipeline at the American Society of Haematology (ASH) Annual Meeting.  Imviva will reveal progress in allogeneic cell therapy candidates being developed for multiple haematological conditions, including T-cell acute lymphoblastic leukaemia, lymphoblastic lymphoma, acute myeloid leukaemia, B-cell… Read More

#Cancer Research #News

Knee x-ray
#Cancer research #CAR-T #Osteosarcoma

OSI awards $1.5 million to advance osteosarcoma treatments 

The Osteosarcoma Institute (OSI) has awarded over $1.5 million in research funding to four projects aiming to advance the treatment of osteosarcoma.  The OSI, which works to increase treatment options and survival rates in osteosarcoma patients, has awarded sums between $125,000 and $500,000 to projects in the field.  OSI Director Dr Lee Helman… Read More

#Business & Investment #News

Researcher in lab
#Cancer research #CAR-T #Leucid Bio

Leucid Bio establishes proof-of-concept for CAR-T therapy 

Biotechnology company Leucid Bio has established proof-of-concept for CAR-T therapy LEU011 for the treatment of solid tumours.  LEU011 is being evaluated in the ongoing AERIAL trial, but data has established proof-of-concept by demonstrating key biological activity through evidence of encouraging pharmacokinetic (PK) and pharmacodynamic (PD) profiles. Analysis… Read More

#Cancer Research #News

T cells
#CAR-T #Cell therapy #Drug discovery #Webinar

Watch now: Technology & techniques to advance T cell therapy

Accelerate your CAR-T research. Watch this on-demand webinar ‘Next-generation tools for CAR-T and T cell therapy research’ to discover high-throughput imaging innovations for assessing cytotoxicity, T cell activation, and proliferation across 2D/3D models. Get proven methods and actionable insights to optimise constructs and scale up your translational assays. You… Read More

Webinar date:
Brought to you by Agilent
#News

T cells
#CAR-T #Cell therapy #Drug discovery #Webinar

Technology & techniques to advance your T cell therapy

Accelerate your CAR-T research. Discover high-throughput imaging innovations for assessing cytotoxicity, T cell activation, and proliferation across 2D/3D models. Get proven methods and actionable insights to optimise constructs and scale up your translational assays. You will learn: Ways to evaluate immune cell behavior and function Practical strategies for optimising your… Read More

Webinar date:
Brought to you by Agilent
#Webinars

CAR-T therapy
#Autoimmune disease #Bristol Myers Squibb #CAR-T #Cell therapy #Lupus

BMS’s CAR-T shows potential for immune reset in lupus

Bristol Myers Squibb has shared its first results in chronic, refractory autoimmune diseases from the Phase I Breakfree-1 study of its investigational, autologous CD19-targeted NEX-T CAR T cell therapy BMS-986353 (CC-97540).   The data evaluates a total of 71 treated patients across the systemic sclerosis (SSc), systemic lupus… Read More

#Editor's Choice #News

CAR T-cells attacking a cancer cell
#Bristol Myers Squibb #CAR-T #Cell therapy #In vivo #Mergers and acquisitions

BMS boosts cell therapy portfolio with Orbital acquisition

Bristol Myers Squibb has announced plans to acquire in vivo CAR-T company Orbital Therapeutics for $1.5 billion.  The acquisition includes Orbital’s lead RNA immunotherapy preclinical candidate currently in IND-enabling studies, OTX-201, which comprises an optimised circular RNA encoding a CD19-targeted CAR for in vivo expression delivered via targeted lipid nanoparticles… Read More

#Business & Investment #News

Human cell
#AI / data analytics / healthtech / informatics #bit bio #CAR-T #Cell therapy #Data security #Stem cells

New podcast: Overcoming barriers to patient access

This is the latest episode of the free DDW narrated podcast, titled “Overcoming barriers to patient access”, which covers two articles written for DDW Volume 25 – Issue 1, Winter 2023/24. They are called: “Scaling up: The need for human cells to give better access to cell therapies” and… Read More

#News

CAR-T cell therapy
#Autoimmune disease #CAR-T #Cell therapy #Immunotherapy #Ulcerative colitis (UC)

First use of CAR-T therapy to treat ulcerative colitis

A team of physicians at the German Center for Immunotherapy at Erlangen University Hospital has succeeded for the first time worldwide in treating a 21-year-old female patient with therapy-resistant, severe chronic inflammatory bowel disease (ulcerative colitis) using cell therapy with CD19 CAR-T cells.  The 21-year-old patient had… Read More

#Editor's Choice #News

Healthy cells
#CAR-T #Cell therapy #FDA #United States

FDA cracks down on overseas cell processing for clinical trials

The US Food and Drug Administration (FDA) has prohibited new clinical trials that send US patients’ live cells overseas, including to China, for gene editing and return infusion.   While the scope and impact are unclear, smaller cell and gene therapy companies that rely on foreign manufacturing may… Read More

#News

CAR-T cell attacking cancer
#CAR-T #Cell therapy #In vivo #Kite Pharma #Mergers and acquisitions

Kite acquires in vivo CAR-T developer for $350 million

Gilead-owned Kite has entered into a definitive agreement to acquire Interius BioTherapeutics, a privately held biotechnology company developing in vivo CAR therapeutics, for $350 million.  The acquisition complements Kite’s focus on cell therapy by incorporating Interius’s integrating in vivo platform.   This approach enables the generation of CAR T-cells directly within… Read More

#Business & Investment #News

#Cancer vaccine #CAR-T #Cell therapy #Immunotherapy #Oncology

New DDW Highlights podcast: 19 August 2025

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. This week has seen some incredible advances in immunotherapy, including the development of a therapy… Read More

#News

Non-Hodgkins lymphoma
#CAR-T #Cell therapy #Lymphoma #Natural killer cells #Phase I trial

CAR-NK therapy treats incurable lymphoma in Phase I trial

In a Phase I trial, single-agent CD19 CAR-NK natural killer cell therapy has achieved complete responses in two patients with third-line Waldenstrom macroglobulinemia (WM), a type of non-Hodgkins lymphoma (NHL).  QUILT-106 is a first-in-human trial evaluating the safety and preliminary efficacy of CD19 CAR-NK cell therapy alone… Read More

#Cancer Research #News #Trending News

#Cancer vaccine #CAR-T #Cell therapy #Immunotherapy #Oncology

This week in drug discovery (11-15 August) 

News round-up for 11-15 August by DDW Senior Digital Content Editor Diana Turner. This week has seen some incredible advances in immunotherapy, including the development of a therapy that combines natural killer and CAR-T cells, and an off-the-shelf cancer vaccine that could revolutionise treatment for patients with one… Read More

#News